Impact Biomedical Inc.
IBO NYSE Pharmaceutical Preparations Financials FY2022โFY2025
Last close ยท Oct 23, 2026
$3.60
5.3%
Revenue
Total sales reported in the income statement.
$0.0M
vs prior year
Operating margin
Operating income as a share of revenue.
โ13,381.3%
Net income
Profit after all expenses, interest and tax.
โ$11.8M
Free cash flow
Cash from operations minus capital spending.
โ
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ
Market cap
Last close times the latest diluted share count, so it is approximate.
โ
Oct 23 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
4.1x
On $0.88 EPS (TTM)
What Impact Biomedical Inc. does
No business description yet.
- Legal name
- IMPACT BIOMEDICAL INC.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K ยท Mar 11, 2026
- Accession ยท CIK
- 0001493152-26-009711
0001834105
Revenue and margins
Impact Biomedical Inc. had $0.0M of revenue in fiscal 2025.
FY22
Revenue $0.1M
FY23
Revenue โ
FY24
Revenue โ
FY25
Revenue $0.0M
Q3 '23
Revenue โ
Q4 '23
Revenue โ
Q1 '24
Revenue โ
Q2 '24
Revenue โ
Q3 '24
Revenue โ
Q4 '24
Revenue โ
Q1 '25
Revenue โ
Q2 '25
Revenue $0.0M
Q3 '25
Revenue $0.0M
Q4 '25
Revenue $0.0M
Q1 '26
Revenue $0.0M
Q2 '26
Revenue $0.0M
FY22
Gross โ
Operating โ6,808.0%
Net โ14,510.0%
FCF โ
FY23
Gross โ
Operating โ
Net โ
FCF โ
FY24
Gross โ
Operating โ
Net โ
FCF โ
FY25
Gross โ1,225.0%
Operating โ13,381.3%
Net โ36,993.8%
FCF โ
Gross
Operating
Net
FCF
Q3 '23
Gross โ
Operating โ
Net โ
FCF โ
Q4 '23
Gross โ
Operating โ
Net โ
FCF โ
Q1 '24
Gross โ
Operating โ
Net โ
FCF โ
Q2 '24
Gross โ
Operating โ
Net โ
FCF โ
Q3 '24
Gross โ
Operating โ
Net โ
FCF โ
Q4 '24
Gross โ
Operating โ
Net โ
FCF โ
Q1 '25
Gross โ
Operating โ
Net โ
FCF โ
Q2 '25
Gross 85.7%
Operating โ16,471.4%
Net โ204,942.9%
FCF โ
Q3 '25
Gross 94.4%
Operating โ5,266.7%
Net โ8,166.7%
FCF โ
Q4 '25
Gross โ5,928.6%
Operating โ16,714.3%
Net 74,928.6%
FCF โ
Q1 '26
Gross โ
Operating โ32,700.0%
Net โ32,671.4%
FCF โ
Q2 '26
Gross 66.7%
Operating โ23,400.0%
Net โ23,300.0%
FCF โ
Gross
Operating
Net
FCF
Net income and earnings per share
Loss periods are shown in red.
FY22
Net income โ$7.3M
FY23
Net income โ$4.3M
FY24
Net income โ$24.7M
FY25
Net income โ$11.8M
Q3 '23
Net income โ$1.2M
Q4 '23
Net income โ$1.2M
Q1 '24
Net income โ$1.0M
Q2 '24
Net income โ$0.9M
Q3 '24
Net income $4.2M
Q4 '24
Net income โ$27.1M
Q1 '25
Net income โ$1.3M
Q2 '25
Net income โ$14.3M
Q3 '25
Net income โ$1.5M
Q4 '25
Net income $5.2M
Q1 '26
Net income โ$2.3M
Q2 '26
Net income โ$0.7M
FY22
Diluted EPS โ$0.10
FY23
Diluted EPS โ$0.07
FY24
Diluted EPS โ$2.30
FY25
Diluted EPS โ$0.38
Q3 '23
Diluted EPS โ$0.02
Q4 '23
Diluted EPS โ$0.02
Q1 '24
Diluted EPS โ$0.10
Q2 '24
Diluted EPS โ$0.09
Q3 '24
Diluted EPS $0.06
Q4 '24
Diluted EPS โ$2.17
Q1 '25
Diluted EPS โ$0.11
Q2 '25
Diluted EPS โ$1.18
Q3 '25
Diluted EPS โ$0.12
Q4 '25
Diluted EPS $1.03
Q1 '26
Diluted EPS โ$0.02
Q2 '26
Diluted EPS โ$0.01
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY22
Return on capital โ
Return on equity โ24.5%
Return on assets โ15.6%
FY23
Return on capital โ
Return on equity โ15.8%
Return on assets โ9.5%
FY24
Return on capital โ
Return on equity โ167.6%
Return on assets โ76.1%
FY25
Return on capital โ
Return on equity โ142.9%
Return on assets โ62.8%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was โ in fiscal 2025, โ of revenue. Cash from operations minus capital spending.
FY22
Free cash flow โ
FY23
Free cash flow โ
FY24
Free cash flow โ
FY25
Free cash flow โ
FY22
Cash from operations โ$2.2M
Capital spending โ
FY23
Cash from operations โ$2.9M
Capital spending โ
FY24
Cash from operations โ$2.9M
Capital spending โ
FY25
Cash from operations โ$1.9M
Capital spending โ
Cash from operations
Capital spending
Q3 '23
Cash from operations โ$0.7M
Capital spending โ
Q4 '23
Cash from operations โ$0.4M
Capital spending โ
Q1 '24
Cash from operations โ$0.5M
Capital spending โ
Q2 '24
Cash from operations โ$0.4M
Capital spending โ
Q3 '24
Cash from operations โ$1.0M
Capital spending โ
Q4 '24
Cash from operations โ$1.0M
Capital spending โ
Q1 '25
Cash from operations โ$0.7M
Capital spending โ
Q2 '25
Cash from operations โ$0.7M
Capital spending โ
Q3 '25
Cash from operations โ$0.6M
Capital spending โ
Q4 '25
Cash from operations $0.1M
Capital spending โ
Q1 '26
Cash from operations โ$0.5M
Capital spending โ
Q2 '26
Cash from operations $0.5M
Capital spending โ
Cash from operations
Capital spending
Dividends, buybacks and share count
Impact Biomedical Inc. returned โ to shareholders in fiscal 2025. The diluted share count rose 0.0%.
FY22
Dividends โ
Buybacks โ
FY23
Dividends โ
Buybacks โ
FY24
Dividends โ
Buybacks โ
FY25
Dividends โ
Buybacks โ
Dividends
Buybacks
FY22
Diluted shares โ
FY23
Diluted shares โ
FY24
Diluted shares โ
FY25
Diluted shares โ
Balance sheet
Cash, debt and the ratios that show how comfortably Impact Biomedical Inc. can carry it.
FY22
Cash $0.0M
Debt โ
FY23
Cash $0.0M
Debt โ
FY24
Cash $2.0M
Debt โ
FY25
Cash $0.0M
Debt โ
Cash
Debt
| Fiscal year end | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Cash and short-term investments | $0.0M | $0.0M | $2.0M | $0.0M |
| Interest coverage | โ7.4x | โ9.1x | โ27.0x | โ5.4x |
| Current ratio | 0.0x | 0.0x | 0.3x | 0.4x |
| Quick ratio | 0.0x | 0.0x | 0.3x | 0.3x |
| Total assets | $46.5M | $44.6M | $20.3M | $17.4M |
| Total liabilities | $13.8M | $16.4M | $13.1M | $1.9M |
| Shareholders' equity | $29.6M | $25.2M | $4.3M | $12.3M |
| Net debt (โ = net cash) | โ | โ | โ | โ |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โPlanโ marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
โ
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8โ9 is strong, 0โ2 weak.
| Test | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Net income is positive | โ | โ | โ | โ |
| Cash from operations is positive | โ | โ | โ | โ |
| Return on assets rose | โ | โ | โ | โ |
| Cash from operations exceeds net income | โ | โ | โ | โ |
| Debt fell relative to assets | โ | โ | โ | โ |
| Current ratio rose | โ | โ | โ | โ |
| Share count didn't rise | โ | โ | โ | โ |
| Gross margin rose | โ | โ | โ | โ |
| Revenue rose relative to assets | โ | โ | โ | โ |
| F-score | โ / 3 | โ / 5 | โ / 5 | โ / 5 |
| Accruals ratio | โ10.8% | โ3.3% | โ67.3% | โ52.8% |
| Altman Z'' | โ0.33 | โ1.82 | โ17.60 | โ4.22 |
4 years of figures
Amounts in USD. Hover a ratioโs name for its definition.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.1M | โ | โ | $0.0M |
| Gross profit | โ | โ | โ | โ$0.4M |
| Research and development | $1.2M | $1.7M | $0.3M | $0.3M |
| Operating income | โ$3.4M | โ$4.0M | โ$28.8M | โ$4.3M |
| Interest expense | $0.5M | $0.4M | $1.1M | $0.8M |
| Pretax income | โ$7.9M | โ$4.4M | โ$24.7M | โ$14.5M |
| Income tax | โ$0.6M | โ | $0.0M | โ$2.6M |
| Net income | โ$7.3M | โ$4.3M | โ$24.7M | โ$11.8M |
| Net income to common | โ$7.1M | โ$4.3M | โ | โ |
| Diluted EPS | โ$0.10 | โ$0.07 | โ$2.30 | โ$0.38 |
| Cash flow | ||||
| Cash from operations | โ$2.2M | โ$2.9M | โ$2.9M | โ$1.9M |
| Depreciation and amortization | $1.1M | $1.1M | $1.1M | $1.1M |
| Stock-based compensation | โ | โ | $0.0M | $0.0M |
| Balance sheet | ||||
| Cash and short-term investments | $0.0M | $0.0M | $2.0M | $0.0M |
| Current assets | $0.1M | $0.3M | $2.4M | $0.4M |
| Current liabilities | $10.6M | $13.1M | $9.8M | $1.2M |
| Inventory | โ | โ | โ | $0.1M |
| Property and equipment, net | $0.3M | $0.3M | $0.0M | โ |
| Goodwill | $25.1M | $25.1M | $25.1M | โ |
| Intangible assets | $20.0M | $18.9M | $17.8M | $17.0M |
| Total assets | $46.5M | $44.6M | $20.3M | $17.4M |
| Total liabilities | $13.8M | $16.4M | $13.1M | $1.9M |
| Preferred stock | โ | $0.1M | $0.1M | โ |
| Shareholders' equity | $29.6M | $25.2M | $4.3M | $12.3M |
| Margins | ||||
| Gross margin | โ | โ | โ | โ1,225.0% |
| Operating margin | โ6,808.0% | โ | โ | โ13,381.3% |
| EBITDA margin | โ4,582.0% | โ | โ | โ9,803.1% |
| Net margin | โ14,510.0% | โ | โ | โ36,993.8% |
| Returns | ||||
| Return on capital employed | โ9.5% | โ12.8% | โ273.7% | โ26.4% |
| Return on equity | โ24.5% | โ15.8% | โ167.6% | โ142.9% |
| Return on assets | โ15.6% | โ9.5% | โ76.1% | โ62.8% |
| Financial health | ||||
| Interest coverage | โ7.4x | โ9.1x | โ27.0x | โ5.4x |
| Current ratio | 0.0x | 0.0x | 0.3x | 0.4x |
| Quick ratio | 0.0x | 0.0x | 0.3x | 0.3x |
| Capital allocation | ||||
| Stock comp / revenue | โ | โ | โ | 40.6% |
| Quality scores | ||||
| Altman Z'' | โ0.3 | โ1.8 | โ17.6 | โ4.2 |
| Accruals ratio | โ10.8% | โ3.3% | โ67.3% | โ52.8% |
Source: SEC EDGAR XBRL filings (CIK 0001834105). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ not investment advice. Check the original filings before relying on any figure.